Savient Submits Biologics License Application (BLA) for p...(otherimportant factors set forth more fu...)

Date:10/31/2008

other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT-I

Contact:

Mary Coleman Kelly Sullivan/Ed Trissel

Savient Pharmaceuticals, Inc. Joele Frank, Wilkinson Brimmer Katcher

information@savient.com ksullivan@joelefrank.com /

(732) 418-9300 etrissel@joelefrank.com

(212) 355-4449

'/>"/>

SOURCE Savient Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. MedImmune Submits Biologics License Application to FDA for Motavizumab